Teri joined the team at the National Bleeding Disorders Foundation in November 2022, to launch, lead and manage the new National Bleeding Disorders Foundation Venture Fund, LLC known as Pathway to Cures (P2C). The fund is focused on equity investments in companies developing therapies for inheritable blood and bleeding disorders. Teri has been in the business of commercializing early-stage research results for over 35 years and most recently as the founding managing director of IU Ventures’ Indiana Philanthropic Venture Fund. Teri served as a senior executive for business development for Cold Spring Harbor Laboratory, Mount Sinai School of Medicine in NYC, was the founding chief executive of Cambridge Enterprise Ltd in Cambridge England and a co-founder of ARCH development partners an early-stage Midwest venture fund.
Her career has been about starting, re-organizing, and leading technology transfer programs and launching new early-stage funds that invest in science-based ventures. Teri has been an advisor to policymakers, universities, and companies; a past President of the Association of University Technology Managers (AUTM), a Bye-Fellow of Christ’s College Cambridge in England, and an Indiana Sagamore of the Wabash.
Tim has been involved in the bleeding disorders community since 2004. He serves as Venture Principal for P2C carrying out venture investment work. Tim provides contracts oversight, sourcing and evaluating investment opportunities, developing business and investment cases, drafting and managing investment transactions with external counsel, and managing post-deal relationships with biotech companies. His previous experience includes clinic and pharmacy operations management and national accounts contracting for a national specialty pharmaceutical distributor. Tim holds a Master of Business Administration degree from Eastern Illinois University.
Dr. Valentino most recently served as President and CEO of the National Bleeding Disorders Foundation (NBDF) and was instrumental in bringing Pathway to Cures into reality. In the role of Entrepreneur in Residence, Dr. Valentino will provide his medical, scientific, and industry knowledge to offer insight and advice into the best and highest-impact investment opportunities to advance the health outcomes and overall wellness of people living with inheritable blood and bleeding disorders. Prior to leading NBDF, Dr. Valentino served as a senior leader at Spark Therapeutics, Shire, and Baxalta. He founded and directed the Hemophilia and Thrombophilia Center at Rush University Medical Center in Chicago and has led numerous clinical trials and published more than 150 papers on hemophilia and other bleeding disorders.
Peter Harvey serves as the Chief Business Officer for NBDF including oversight for finance & accounting, business development, conference & travel services, payer relations, and IT. Peter is a senior healthcare finance and operations executive with diverse experience in healthcare nonprofit finance & accounting, pharma/biotech HEOR and medical affairs business operations, academic medical/pediatric department and Hemophilia Treatment Center administration, plus PM&R medical practice and research foundation executive leadership. Peter has volunteered at a number of non-profits and is a founding volunteer board member of a nonprofit providing education and humanitarian support to children and families in Mariani, Haiti. He has a B.A. in Biology from Augustana College and a M.B.A. from the University of Chicago, Booth School of Business in Finance and Healthcare.
Philip M. Gattone, M.Ed., is the president and chief executive officer of the National Bleeding Disorders Foundation (NBDF).
Gattone is a seasoned leader dedicated to amplifying the impact of nonprofit organizations through his distinctive blend of leadership and strategic insight. As the previous president & CEO of the Epilepsy Foundation, Gattone orchestrated unprecedented growth, expanding the organization’s reach and influence. Through innovative partnerships and streamlined operations, he spearheaded record-breaking community engagement and financial performance. Under his stewardship, annual revenues surged from $10 million in 2012 to over $25 million in 2020, marking a significant milestone in the Foundation’s trajectory. Gattone’s collaborative approach also forged alliances with key stakeholders, bolstering the Foundation’s standing within the national and global epilepsy community.
Prior to his transformative role at the Epilepsy Foundation, Gattone elevated community impact and served as a senior executive in local, regional, national, and global nonprofit organizations and healthcare companies. His experiences provide a rare perspective and deep understanding of the unique needs facing nonprofit and healthcare company leaders.
Gattone earned his bachelor’s degree in business and marketing from Bradley University and his master’s degree in education from National Louis University in Chicago. He resides in North Carolina with his wife, Jill, where they remain steadfast in their commitment to making a difference in the epilepsy and bleeding disorders community and beyond.
Dawn has been a leader in the bleeding disorders community for many years. As a parent of a son with hemophilia, she founded the Rocky Mountain Hemophilia & Bleeding Disorders Association in Bozeman, Montana, served as its Executive Director, and began their Family Camp. After moving to Pittsburgh, Pennsylvania, Dawn worked for the American Diabetes Association (ADA) as an Area Manager. Concurrently, she served as a board member for the Hemophilia Center of Western Pennsylvania for six years. Dawn left the ADA for a position as the Executive Director of the Western Pennsylvania Chapter of the NBDF in Pittsburgh, where she became actively involved with Camp Hot to Clot and eventually became the Director. She holds a Bachelor of Science from Montana State University in Bozeman.
Scott Martin is a private investor based in Houston, Texas. He has a son with severe hemophilia and has worked to improve the lives of people with bleeding disorders by supporting the Lone Star Chapter. He is the Former Chair of the NBDF Board. In addition, he co-founded Inspiration Biopharmaceutical, a factor manufacturing company that initiated two products that today are owned and marketed by Shire and Aptevo. Scott was also co-founder of Martin Midstream Partners (NASDAQ; MMLP) and serves on several non-profit and profit boards.
Dr. Dunn is a Professor of Pediatrics at Nationwide Children’s Hospital/Ohio State University where she is the Director of Pediatric Hematology and directs the Hemophilia Treatment Center. Dr. Dunn received her medical degree from Wright State University School of Medicine in Dayton, Ohio and completed her pediatric and pediatric hematology/oncology training at Emory University in Atlanta, Georgia. Dr. Dunn is a member of various professional associations including the American Society of Hematology, World Federation of Hemophilia, The International Society of Thrombosis and Hemostasis, the International Prophylaxis Study Group and the Hemophilia and Thrombosis Research Society (HTRS). She is the Vice-President of the World Federation of Hemophilia, USA, a board member of the National Bleeding Disorders Foundation (NBDF), and the Chair of Medical and Scientific Advisory Council (MASAC) for the NBDF. Dr. Dunn has also received multiple awards, including the US News and World Report Top Doctors, and was the National Bleeding Disorders Foundation Physician of the Year for 2020.
Sharon Richardson, PhD is a result-driven strategist with 28 years of experience in the pharmaceutical industry as a medical affairs leader committed to creating healthier communities through scientific exchange, patient advocacy, and community engagement.
Dr. Richardson previously served as Executive Director, US Medical Affairs Operations at Astellas Pharma; US Head of Medical Affairs at Spark Therapeutics; VP, US Medical Affairs at Baxter (Baxalta, Shire), and VP, US Medical Affairs at Eisai Inc. Currently, Dr Richardson serves as an advisor to Advance-Africa Commercial Solutions Inc. in Ghana and as a Director on the National Bleeding Disorders Foundation Board.
Dr. Richardson earned a Doctor of Philosophy degree in Pharmacology from Howard University in Washington DC, Postdoctoral Fellowship in Neuroscience at the University of Pennsylvania in Philadelphia, and Bachelor of Science degree in Pathobiology from the University of Connecticut.
Dr. White is a Hematologist and researcher currently serving as an Adjunct Professor of Medicine and Pharmacology at University North Carolina Chapel Hill (UNCCH). Dr. White received his medical degree from UNCCH in 1971 and returned to UNCCH after his internship and residency at Georgetown University. Dr. White served UNCCH in various roles over the years, including as an Instructor, Assistant Professor, and Associate Professor in the Department of Medicine, a Member of the Dental Research Center, a Professor in the Department of Medicine and the Department of Pharmacology, the Associate Director and Director of the Comprehensive Hemophilia Diagnostic and Treatment Center, and the Associate Director and Director of the Center for Thrombosis and Hemostasis. He last served as the John C. Parker Distinguished Professor of Medicine and Pharmacology from 1999 to 2004. Following this, Dr. White joined Versiti, a Milwaukee, Wisconsin-based blood health organization, where he served as the Executive Vice President for Research, Director, and Chief Scientific Officer of the Versiti Blood Research Institute. He also served as the Richard H. and Sara E. Aster Chair for Medical Research at the Versiti Blood Center of Wisconsin (formerly known as the BloodCenter of Wisconsin) and is currently designated as a Senior Investigator Emeritus. He is also an Emeritus Associate Director of the Medical Scientist Training Program at the Medical College of Wisconsin, where he previously served as the Associate Dean for Research. He is a Director at the Great Lakes Hemophilia Foundation. He was also appointed as an Adjunct Professor at the Milwaukee School of Engineering (MSOE), Marquette University, and the University of Wisconsin-Milwaukee (UWM) previously. Other than that, he served as a Director at the National Bleeding Disorders Foundation and the Leukemia & Lymphoma Society, and as a Member of the Advisory Council at the National Heart, Lung, and Blood Institute (NHLBI).
Philip M. Gattone, M.Ed., is the president and chief executive officer of the National Bleeding Disorders Foundation (NBDF).
Gattone is a seasoned leader dedicated to amplifying the impact of nonprofit organizations through his distinctive blend of leadership and strategic insight. As the previous president & CEO of the Epilepsy Foundation, Gattone orchestrated unprecedented growth, expanding the organization’s reach and influence. Through innovative partnerships and streamlined operations, he spearheaded record-breaking community engagement and financial performance. Under his stewardship, annual revenues surged from $10 million in 2012 to over $25 million in 2020, marking a significant milestone in the Foundation’s trajectory. Gattone’s collaborative approach also forged alliances with key stakeholders, bolstering the Foundation’s standing within the national and global epilepsy community.
Prior to his transformative role at the Epilepsy Foundation, Gattone elevated community impact and served as a senior executive in local, regional, national, and global nonprofit organizations and healthcare companies. His experiences provide a rare perspective and deep understanding of the unique needs facing nonprofit and healthcare company leaders.
Gattone earned his bachelor’s degree in business and marketing from Bradley University and his master’s degree in education from National Louis University in Chicago. He resides in North Carolina with his wife, Jill, where they remain steadfast in their commitment to making a difference in the epilepsy and bleeding disorders community and beyond.
Dr. Recht serves as the Chief Medical and Scientific Officer (CMSO) of Pathway to Cures and National Bleeding Disorders Foundation (NBDF) and serves as a member of NBDF’s Medical and Scientific Advisory Council (MASAC).
An internationally respected leader in pediatric hematology, Dr. Recht is a Professor of Clinical Pediatrics and member of the Hemophilia Treatment Center and Section of Pediatric Hematology-Oncology at Yale University School of Medicine where he cares for children, adolescents, and young adults affected by bleeding and clotting disorders.
Dr. Recht most recently served as the Chief Science Officer for the American Thrombosis and Hemostasis Network (ATHN) where he worked at the strategic and policy level to inform the scientific direction of the organization. He was also Director of the Hemophilia Center at Oregon Health & Science University (OHSU) from 2007 until 2020 and Director of the Mountain States Hemophilia Network, a collaboration of hemophilia treatment centers in the western United States.
He has also participated in over 110 clinical research trials testing new treatments for children with bleeding and clotting disorders, including being a leader in research involving gene therapy for hemophilia.
Dr. Sylvia Fong is an independent consultant and Adjunct Associate Professor at Queen’s University in Canada, specializing in gene therapy, including AAV, gene editing, and non-viral platforms. With over 25 years of R&D experience, she is recognized for pioneering the development of the first approved AAV-based gene therapy for hemophilia A, successfully leading the program from research through regulatory approval and life-cycle management.
At BioMarin Pharmaceutical Inc., Dr. Fong held several key roles, including Executive Director and Head of Non-Oncology Hematology Research, where she oversaw programs for hemophilia, von Willebrand disease, hereditary hemorrhagic telangiectasia, thalassemia, and sickle cell disease. Earlier in her tenure as Director and Senior Director, she led the translational development of therapies for metabolic, cardiovascular, and lysosomal storage disorders, advancing multiple programs from preclinical to clinical stages.
Dr. Fong’s expertise spans the development of biologics, gene therapies, and small molecules, with a strong focus on addressing unmet medical needs in rare genetic diseases. She continues to drive innovation across diverse therapeutic areas and drug modalities, leveraging her extensive experience to support cutting-edge advancements in the field.
Dr. Katherine High is currently a visiting professor at Rockefeller University and serves as a Board member for Incyte Corporation, CRISPR Therapeutics, and Virion Therapeutics. She is a past president of the American Society of Gene and Cell Therapy, and a member of both the National Academy of Medicine and the National Academy of Sciences. Dr. High served as the President, Therapeutics of Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, and as a member of AskBio’s board of directors. Previously, Dr. High co-founded Spark Therapeutics, Inc. and from September 2014 to December 2019, she served as President and as a member of the board of directors and served as Head of Research & Development from September 2017 to February 2020. From 1992 to 2014, Dr. High was a Professor at the Perelman School of Medicine at the University of Pennsylvania, an Investigator at Howard Hughes Medical Institute, Director of the Center for Cellular and Molecular Therapeutics, and attending physician at the Children’s Hospital of Philadelphia. She completed a five-year term from 2000 to 2005 on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue, and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy.
Recognized for her pioneering research and development of gene therapies for genetic disease. She is known for her studies in adeno-associated viral (AAV)-mediated gene therapy for hemophilia, including the development of AAV vectors that brought about long-term improvement in small and large animal models of hemophilia. She translated these findings to studies of men with severe hemophilia and overcame hurdles identified in clinical trials including the risk of germline transmission and human immune response to the AAV vector.
Dr. High earned her undergraduate degree in Chemistry at Harvard, an M.D. from the University of North Carolina School of Medicine, and completed medical training in Hematology at Yale. Dr. High has a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an honorary M.A. from The University of Pennsylvania.
Haiyan Jiang, PhD, is a co-founder and Chief Scientific Officer at PointLoma BioSciences. Dr. Jiang has a proven track record in drug development from research to IND and BLA, specialized in translational research and preclinical development. Dr. Jiang has extensive and in-depth experience in cell and gene therapy, viral vectors and genome editing, and more recently, on developing genetically engineered innate cellular therapy for cancer. Dr. Jiang has made vital contributions to the development of EDIT-101 and EDIT-301 at Editas Medicine, Eloctate and Alprolix at Biogen, and Jivi at Bayer. She was a co-inventor of Altuviiio. She started her research on AAV-mediated gene therapy for hemophilia A and B at Avigen in 2001. She has 45 peer-reviewed publications and 21 granted US patents. Dr. Jiang received her Ph.D. in oncology at University of Wisconsin-Madison, and postdoctoral training at University of California, San Francisco.
Dr. Glenn Pierce is currently an independent consultant, entrepreneur-in-residence at Third Rock Ventures, serves on the World Federation of Hemophilia (WFH) and WFHUSA Board of Directors, and the Medical and Scientific Advisory Council of the National Bleeding Disorders Foundation (NBDF). Dr. Pierce is also a Director of Voyager Therapeutics and Global Blood Therapeutics, two publicly held biotechnology companies. Dr. Pierce retired from Biogen in 2014 as Senior Vice President of Hematology, Cell and Gene Therapies. He had overall R&D responsibility for hemophilia and hemoglobinopathies and led the research and clinical development of extended half-life FVIII and FIX Fc fusions as Chief Medical Officer since joining the company in 2009, culminating in multiple regulatory approvals beginning in 2014. Dr. Pierce spearheaded the initiation of a 5-year Humanitarian Aid clotting factor distribution program with WFH, and My Life Our Future, a population-wide genomic biobank initiative with NBDF and other partners.
Dr. Pierce has 30 years’ experience in biotechnology research and development, from the bench to the bedside in small, large, public and private biotech/biopharma firms, including Biogen, Bayer, Inspiration, Avigen, Selective Genetics, and Amgen in the areas of tissue regeneration and hematology. He is the co-author of more than 150 scientific papers and has been awarded over 15 patents. Dr. Pierce served on the Medical and Scientific Advisory Council, the Board of Directors, and was President of the Board of the National Hemophilia Foundation (U.S.) spanning 1983-2005. Dr. Pierce also served on the Blood Products Advisory Committee at the US FDA and the Committee on Blood Safety and Availability at the US Department of Health and Human Services. He received an MD and a PhD in Immunology, both from Case Western Reserve University in Cleveland, Ohio and did his postgraduate training in pathology and hematology research at Washington University in St. Louis, Missouri.
Dr. Steven Pipe is a Professor and the Laurence A. Boxer Research Professor of Pediatrics and Professor of Pathology at the University of Michigan, Ann Arbor, Michigan. He is the Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program and Medical Director of the Special Coagulation Laboratory. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr. Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A. He has been actively involved in clinical trials with novel therapeutics for hemophilia including gene therapy. He was the 2015 recipient of the Leadership in Research Award from the National Bleeding Disorders Foundation. He has served on the Board of Directors for the Hemostasis and Thrombosis Research Society, as Chair of the Board of Directors for the American Thrombosis and Hemostasis Network, and currently as a member of the Medical and Scientific Advisory Committee of the National Bleeding Disorders Foundation.
Dr. Valentino currently serves as the Chief Executive Officer of Pathway to Cures in addition to President & Chief Executive Officer of National Bleeding Disorders Foundation. For over three decades he treated families with bleeding disorders, working towards finding better treatments for patients and preventing complications of their disorders through education, advocacy, and research. Conducting clinical and laboratory research helped him to understand how to develop and elevate treatments to new levels, seeking cures and improving the quality of life for everyone in the bleeding disorders community. He has worked in the biopharmaceutical industry trying to understand how to bring new therapies to patients globally. His past experiences as a physician, educator, researcher, and an industry partner have all focused on treating patients and their families and have provided him with the experiences and knowledge to lead the National Bleeding Disorders Foundation and Pathway to Cures.
This is an exciting time for the bleeding disorders community as research is progressing forward in unimaginable ways, but there is still more to be done. Research is one of his primary objectives, to increase funding to support innovative research on new therapies, and then educating stakeholders on these advancements.
